Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 11
eFFECTOR Therapeutics Raises Additional USD16 Million in Series B Financing Round 13
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 14
eFFECTOR Therapeutics Raises Additional USD14.6 Million in Financing Round 16
Effector Therapeutics Raises US$45 Million In Series A Financing 17
Partnerships 19
eFFECTOR Therapeutics Enters into Agreement with Merck 19
eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 20
eFFECTOR Therapeutics Inc – Key Competitors 21
eFFECTOR Therapeutics Inc – Key Employees 22
eFFECTOR Therapeutics Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Corporate Communications 24
Mar 23, 2018: eFFECTOR Announces Appointment of John W. Smither to its Board of Directors 24
Product Approvals 25
Mar 09, 2017: Effector Therapeutics Lead Product Candidate, EFT508, Receives Orphan Designation From FDA for Treatment of Diffuse Large B-cell Lymphoma 25
Clinical Trials 26
Jul 27, 2018: eFFECTOR initiates dosing of eFT508 (tomivosertib) in a phase 2 add-on (CPI-A) trial in combination with checkpoint inhibitors to treat patients with insufficient response to checkpoint inhibitors alone 26
Jun 06, 2018: eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma 27
May 11, 2018: eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer 28
Apr 26, 2018: eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry 29
Apr 16, 2018: eFFECTOR to Present Data on eFT508 at the AACR 2018 Annual Meeting 30
Dec 11, 2017: Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile 31
Nov 10, 2017: eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects 32
Oct 04, 2017: eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer 33
Jun 05, 2017: eFFECTOR Therapeutics Presents Phase 1 Data On eFT508, Its Lead Product Candidate, At ASCO 2017 35
Apr 03, 2017: eFFECTOR Therapeutics Presents Positive Preclinical Data on Lead Product Candidate at AACR 2017 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
eFFECTOR Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 11
eFFECTOR Therapeutics Raises Additional USD16 Million in Series B Financing Round 13
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 14
eFFECTOR Therapeutics Raises Additional USD14.6 Million in Financing Round 16
Effector Therapeutics Raises US$45 Million In Series A Financing 17
eFFECTOR Therapeutics Enters into Agreement with Merck 19
eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 20
eFFECTOR Therapeutics Inc, Key Competitors 21
eFFECTOR Therapeutics Inc, Key Employees 22
List of Figures
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
eFFECTOR Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8